Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials

Medical Hypotheses

Volumn 82, Issue 6, 2014, Pages 670-673

  Adamowicz, Jan ^a   Pokrywczyńska, Marta ^a   Drewa, Tomasz ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Nicolaus Copernicus Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BOTULINUM TOXIN; CHEMOKINE; CYCLOSPORIN; CYTOKINE; DIMETHYL SULFOXIDE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GROWTH FACTOR; HEPARIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; KERATINOCYTE GROWTH FACTOR; LIDOCAINE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CULTURE MEDIUM; SIGNAL PEPTIDE;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG EFFICACY; HUMAN; HYPOTHESIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL CYSTITIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL CONDITIONED MEDIUM; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RECURRENT DISEASE; STEM CELL CULTURE; TISSUE REGENERATION; URINARY TRACT; BIOLOGICAL MODEL; CHEMISTRY; CYSTITIS, INTERSTITIAL; INTRAVESICAL DRUG ADMINISTRATION; MESENCHYMAL STROMA CELL; METABOLISM; PHARMACOLOGY;

ADMINISTRATION, INTRAVESICAL; CULTURE MEDIA, CONDITIONED; CYSTITIS, INTERSTITIAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STROMAL CELLS; MODELS, BIOLOGICAL;

EID: 84899647121     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.02.027     Document Type: Article

References (49)

1. Keay S., Kaczmarek P., Zhang C.O., Koch K., Szekely Z., Barchi J.J., et al. Normalization of proliferation and tight junction formation in bladder epithelial cells from patients with interstitial cystitis/painful bladder syndrome by d-proline and d-pipecolic acid derivatives of antiproliferative factor. Chem Biol Drug Des 2011, 77:421-430.
2. Parsons C.L., Tatsis V. Prevalence of interstitial cystitis in young women. Urology 2004, 64:866-870.
3. van Ophoven A., Rossbach G., Oberpenning F., Hertle L. Hyperbaric oxygen for the treatment of interstitial cystitis: long-term results of a prospective pilot study. Eur Urol 2004, 46:108-113.
4. Friedlander J.I., Shorter B., Moldwin R.M. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int 2012, 109:1584-1591.
5. Geirsson G., Wang Y.H., Lindström S., Fall M. Traditional acupuncture and electrical stimulation of the posterior tibial nerve. A trial in chronic interstitial cystitis. Scand J Urol Nephrol 1993, 27:67-70.
6. O'Reilly B.A., Dwyer P.L., Hawthorne G., Cleaver S., Thomas E., Rosamilia A., et al. Transdermal posterior tibial nerve laser therapy is not effective in women with interstitial cystitis. J Urol 2004, 172:1880-1883.
7. Teichman J.M., Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol 2007, 14:3599-3607.
8. Zhang C.O., Wang J.Y., Koch K.R., Keay S. Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis. J Urol 2005, 174:2382-2387.
9. Khandelwal P., Abraham S.N., Apodaca G. Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol 2009, 297:1477-1501.
10. Sairanen J., Tammela T.L., Leppilahti M., Onali M., Forsell T., Ruutu M. Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: a prospective study with cyclosporine A and pentosan polysulfate sodium. Neurourol Urodyn 2007, 26:267-270.
11. Kutlu O., Akkaya E., Koksal I.T., Bassorgun I.C., Ciftcioglu M.A., Sanlioglu S., et al. Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis. Int Urol Nephrol 2010, 42:393-399.
12. Chai T.C., Zhang C.O., Shoenfelt J.L., Johnson H.W., Warren J.W., Keay S. Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol 2000, 163:1440-1444.
13. Altuntas C.Z., Daneshgari F., Sakalar C., Goksoy E., Gulen M.F., Kavran M., et al. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol 2012, 61:193-200.
14. Wu Y., Zhao R.C., Tredget E.E. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 2010, 28:905-915.
15. Drewa T., Adamowicz J., Sharma A. Tissue engineering for the oncologic urinary bladder. Nat Rev Urol 2012, 9:561-572.
16. - cells can differentiate into hematopoietic and endothelial cells. Blood 2011, 118:2105-2115.
17. Adamowicz J., Kowalczyk T., Drewa T. Tissue engineering of urinary bladder - current state of art and future perspectives. CEJU 2013, 202-206.
18. Parolini O., Soncini M., Evangelista M., Schmidt D. Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine?. Regen Med 2009, 4:275-291.
19. Tian H., Bharadwaj S., Liu Y., Ma H., Ma P.X., Atala A., et al. Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering. Biomaterials 2010, 31:870-877.
20. Sharma A.K., Hota P.V., Matoka D.J., Fuller N.J., Jandali D., Thaker H., et al. Urinary bladder smooth muscle regeneration utilizing bone marrow derived mesenchymal stem cell seeded elastomeric poly(1,8-octanediol-co-citrate) based thin films. Biomaterials 2010, 24:6207-6217.
21. Bodin A., Bharadwaj S., Wu S., Gatenholm P., Atala A., Zhang Y. Tissue-engineered conduit using urine-derived stem cells seeded bacterial cellulose polymer in urinary reconstruction and diversion. Biomaterials 2010, 31:8889-8901.
22. Zhang Y., Lin H.K., Frimberger D., Epstein R.B., Kropp B.P. Growth of bone marrow stromal cells on small intestinal submucosa: an alternative cell source for tissue engineered bladder. BJU Int 2005, 96:1120-1125.
23. Ohishi M., Schipani E. Bone marrow mesenchymal stem cells. J Cell Biochem 2010, 109:277-282.
24. Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010, 12:87-117.
25. Eliopoulos N., Zhao J., Forner K., Birman E., Young Y.K., Bouchentouf M. Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice. Mol Ther 2011, 19:2072-2083.
26. Schuleri K.H., Centola M., Choi S.H., Evers K.S., Dawoud F., George R.T., et al. CT for evaluation of myocardial cell therapy in heart failure: a comparison with CMR imaging. JACC Cardiovasc Imaging 2011, 4:1284-1293.
27. Hwang D.Y., Kim D.S., Kim D.W. Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems. J Cell Biochem 2010, 109:292-301.
28. van Haaften T., Byrne R., Bonnet S., Rochefort G.Y., Akabutu J., Bouchentouf M., et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009, 1(180):1131-1142.
29. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132(4):631-644.
30. Meirelles Lda S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20:419-427.
31. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008, 3:1886-1890.
32. Watson S.L., Marcal H., Sarris M., Di Girolamo N., Coroneo M.T., Wakefield D. The effect of mesenchymal stem cell conditioned media on corneal stromal fibroblast wound healing activities. Br J Ophthalmol 2010, 94:1067-1073.
33. Angoulvant D., Ivanes F., Ferrera R., Matthews P.G., Nataf S., Ovize M. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. J Heart Lung Transplant 2011, 30:95-102.
34. Walter M.N., Wright K.T., Fuller H.R., MacNeil S., Johnson W.E. Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Exp Cell Res 2010, 316:1271-1281.
35. Wang C.Y., Yang H.B., Hsu H.S., Chen L.L., Tsai C.C., Tsai K.S., et al. Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats. J Tissue Eng Regen Med 2012, 6:559-569.
36. Southgate J., Varley C.L., Garthwaite M.A., Hinley J., Marsh F., Stahlschmidt J., et al. Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int 2007, 99:1506-1516.
37. Bassuk J.A., Cochrane K., Mitchell M.E. Induction of urothelial cell proliferation by fibroblast growth factor-7 in RAG1-deficient mice. Adv Exp Med Biol 2003, 539:623-633.
38. Popova A.P., Bozyk P.D., Goldsmith A.M., Linn M.J., Lei J., Bentley J.K., et al. Autocrine production of TGF-beta1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells. Am J Physiol Lung Cell Mol Physiol 2010, 298:735-743.
39. Shah M., Foreman D.M., Ferguson M.W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995, 108:985-1002.
40. Woo L.L., Tanaka S.T., Anumanthan G., Pope J.C., Thomas J.C., Adams M.C., et al. Mesenchymal stem cell recruitment and improved bladder function after bladder outlet obstruction: preliminary data. J Urol 2011, 185:1132-1138.
41. Xiang M.X., He A.N., Wang J.A., Gui C. Protective paracrine effect of mesenchymal stem cells on cardiomyocytes. J Zhejiang Univ Sci B 2009, 10:619-624.
42. Lin Y.H., Liu G., Kavran M., Altuntas C.Z., Gasbarro G., Tuohy V.K., et al. Lower urinary tract phenotype of experimental autoimmune cystitis in mouse: a potential animal model for interstitial cystitis. BJU Int 2008, 102:1724-1730.
43. Sairanen J., Forsell T., Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol 2004, 171:2138-2141.
44. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 7:141-150.
45. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
46. Semedo P., Palasio C.G., Oliveira C.D., et al. Early modulation of inflammation by mesenchymal stem cell after acute kidney injury. Int Immunopharmacol 2009, 9:677-682.
47. Togel F., Hu Z.M., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
48. Ortiz L.A., Dutreil M., Fattman C., Pandey A.C., Torres G., Go K., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007, 104:11002-11007.
49. Pokrywczynska M., Jundzill A., Bodnar M., Adamowicz J., Tworkiewicz J., Szylberg L., et al. Do mesenchymal stem cells modulate the milieu of reconstructed bladder wall?. Arch Immunol Ther Exp (Warsz) 2013, 61(6):483-493.